Bristol-Myers Squibb said it has signed an option agreement to buy Galecto Biotech and its experimental pulmonary fibrosis treatment in a deal that could be valued at up to $444 million.
from WSJ.com: US Business http://ift.tt/1wXk7B7
via IFTTT
from WSJ.com: US Business http://ift.tt/1wXk7B7
via IFTTT
No comments:
Post a Comment